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The U.S. Environmental Protection Agency
(EPA) defines cumulative risk as the com-
bined risks from aggregate exposure to multi-
ple stressors (U.S. EPA 2003), and cumulative
risk assessment as an analysis, characterization,
and possible quantification of these risks. In
this and companion papers (Callahan and
Sexton 2007), we explore approaches for
assessing the effects of stressors from multiple
sources (Menzie et al. 2007), the effects of dif-
ferential vulnerability in populations and indi-
viduals (deFur et al. 2007), and the effects
associated with differential exposure (Sexton
and Hattis 2007). 
This article provides an evaluation of
whether and how biomonitoring data can
inform cumulative risk assessment. We exam-
ined the potential for human and ecosystem
biomarkers to help us understand cumulative
health risks from the interactions between
environmental exposures and host susceptibil-
ity factors. We used case studies to address the
question “Can biomarkers enable us to under-
stand and quantify better the population bur-
den of disease and health effects attributable to
environmental exposures? Further, we present
examples from the current literature on the
availability and uses of biomarkers to explore
two other questions: 
• Under what circumstances can biomarkers
be used to disaggregate disease burden into
speciﬁc risk factors? For example, when and
how can biomarkers be linked to speciﬁc dis-
eases, and can a speciﬁc biomarker or set of
biomarkers be useful for mapping disease to
exposure? 
• When and how can biomarkers be used
to infer the source and magnitude of expo-
sure among a set of competing sources and
pathways? 
Speciﬁc health outcomes potentially may
come from numerous differing exposures.
The problem of trying to infer which expo-
sures lead to these outcomes is not simple.
The first of these two questions focuses on
assessing multiple risk factors that may lead
to health outcomes, whereas the latter ques-
tion centers on disaggregating cumulative
exposures into their component parts. In
this article, we use the term “disaggregation”
to address both of these issues, namely, risk
factors leading to a health outcome and
exposures leading to a health outcome.
These are difficult problems that are only
now receiving attention in the scientific
community. 
Biomarkers may offer improved under-
standing of the pathway between the
causative agents, as indicated by exposure
measures, and the health outcome. There
are many challenges and limitations. What
are the public health implications of wide-
spread low-level population exposures that
can now be inferred from biological or eco-
logic measurements? Disaggregating the
health effects and understanding the health
risk from these exposures will require new
perspectives on the environmental health
paradigm. Ideally, biomonitoring will
become a foundation of an environmental
public health tracking system that includes
identification of environmental sources,
exposures, and related population health
outcomes (Barr et al. 2005a). Combining
biomonitoring results with population
health surveillance offers opportunities for
understanding the relationship between
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BACKGROUND: Biomarkers are considered the method of choice for determining exposure to environ-
mental contaminants and relating such exposures to health outcomes. However, the association
between many biomarkers and outcome is not direct because of variability in sensitivity and suscepti-
bility in the individual.
OBJECTIVES: We explore the relationship between environmental exposures and health outcomes as
mitigated by differential susceptibility in individuals or populations and address the question “Can
biomarkers enable us to understand and quantify better the population burden of disease and
health effects attributable to environmental exposures?” 
METHODS: We use a case–study approach to develop the thesis that biomarkers offer a pathway to
disaggregation of health effects into speciﬁc, if multiple, risk factors. We offer the point of view that
a series or array of biomarkers, including biomarkers of exposure, biomarkers of susceptibility, and
biomarkers of effect, used in concert offer the best means by which to effect this disaggregation. We
commence our discussion by developing the characteristics of an ideal biomarker, then give some
examples of commonly used biomarkers to show the strengths and weaknesses of current usage. We
follow this by more detailed case-study assessment outlining the state-of-the-science in specific
cases. We complete our work with recommendations regarding the future use of biomarkers and
areas for continued development.
CONCLUSIONS: The case studies provide examples of when and how biomarkers can be used to
infer the source and magnitude of exposure among a set of competing sources and pathways. The
answer to this question is chemical specific and relates to how well the biomarker matches the
characteristics of an “ideal” biomarker–in particular ease of collection and persistence. The use of
biomarkers in combination provides a better opportunity to disaggregate both source and pathway
contributions.
KEY WORDS: biomarkers of effect, biomarkers of exposure, biomarkers of susceptibility, cumulative
exposure, multiple stressors, risk assessment. Environ Health Perspect 115:833–840 (2007).
doi:10.1289/ehp.9334 available via http://dx.doi.org/ [Online 24 January 2007]cumulative exposures and population, com-
munity, and individual risk. 
Biomarkers As a Possible Basis
for Environmental Regulation
Medical surveillance studies of disease bur-
dens provide insight on cumulative impacts
from multiple risk factors but do not provide a
framework to attribute risk factors to disease.
This attribution is necessary for regulation.
The problem is ﬁnding a measurable basis for
regulation of disease-causing agents that pro-
vides a quantitative or qualitative link or links
between disease and its causative agent(s) in
the environment. Biomarkers in human and
ecologic populations may provide this basis.
Biological exposure indices (BEIs) and biologi-
cal tolerance values (BATs) have been used in
the industrial hygiene community for decades
in an effort to protect workers (Plog et al.
1996); however, only recently have analytical
measurements become sensitive enough to
allow quantiﬁcation of biological measures in
the nonoccupational setting. Thus it has now
become feasible to develop in a framework
upon which to build a better understanding of
the relationship between such measures and
exposures in the community setting. 
We deﬁne biomarkers as measures reﬂect-
ing an interaction between a biological system
and a chemical, biological, or physical envi-
ronmental agent. The focus is on chemical
agents, although the methods developed are
applicable in other areas. The literature usu-
ally considers three classes of biomarkers
[National Research Council (NRC) 1987;
World Health Organization (WHO) 1993]:
biomarkers of exposure, biomarkers of effect,
and biomarkers of susceptibility. The ﬁrst two
link exposures with health outcomes and can
provide the basis for linking biological effect
and exposure to environmental contamina-
tion. The third refers to a modiﬁer that inﬂu-
ences the magnitude of or induces the effect
given a fixed magnitude of the driver. All
three types may be used to identify vulnerable
individuals or populations. Biomarkers of
exposure may include measurements of par-
ent compounds, metabolites, or DNA or pro-
tein adducts of parent compounds and/or
metabolites that indicate that a direct expo-
sure to the compound of interest has
occurred. Biomarkers of effect may include
measurements of changes in the biological
system, e.g., acetylcholinesterase inhibition
associated with organophosphate pesticide
exposures or changes in cytochrome P450
enzyme activity. Biomarkers of susceptibility
may include, for example, polymorphisms in
specific genes associated with metabolism of
toxic material in the body.
Characteristics of an ideal biomarker. We
used the characteristics of an ideal biomarker
to evaluate the current state of research, guide
the use of speciﬁc biomarkers, and to suggest
future research. The literature on the criteria
for defining, developing, and validating an
ideal biomarker (Groopman and Kensler
2005; Metcalf and Orloff 2004; Schulte and
Mazzuckelli 1991; WHO 1993) suggests
seven criteria for evaluating a biomarker’s use-
fulness in cumulative risk assessment. Ideal
biomarkers would:
• be persistent—have a long half-life;
• be easily collected—collected using non-
invasive procedures that present only minor
procedural difficulties in collection, trans-
port, storage, and analysis; 
• be linked to disease—display exposure, indi-
cate effect, and establish a link between them; 
• have a large sample—to examine the distrib-
ution of the biomarker in the population
and to establish links between the bio-
marker and effect, it is important that the
biomarker be found in a substantial fraction
of the population; 
• have broad spatial distribution and temporal
occurrence—a complete spatial and temporal
understanding of the exposure/health out-
come distribution; 
• have sensitivity—sufficiently sensitive to
give information on differences in popula-
tions from different regions and over time
scales of interest, for example, seasonal or
long-term, secular trends; and
• favor measurement of parent compounds
over metabolites—the measurement of par-
ent compound gives a direct and unambigu-
ous measure of exposure to the contaminant
of interest. 
Table 1 presents an outline of considera-
tions for biomarkers, including a hypothetical
biomarker that illustrates the criteria. Table 1
shows that even commonly used biomarkers
are far from ideal but that combinations of
biomarkers for the same compound may give
complementary information. 
An Array of Biomarkers in
Cumulative Risk Assessment
Although a biomarker of exposure may be
appropriate in assessing exposures over one
time scale, health outcomes, and thus risk, may
be associated with time scales markedly differ-
ent from those being assessed. Further, expo-
sure to a speciﬁc compound—a biomarker of
exposure—may be insufﬁcient to assess effects;
a biomarker of effect may be needed. Finally, if
one is concerned about large populations and
the health impact they are likely to experience,
Ryan et al.
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Table 1. A comparison of some biomarkers to an ideal biomarker.
Biomarker Ideal biomarker K Cotinine Blood lead  Serum lead Bone lead
Associated exposure
Type Compound K Nicotine Lead Lead Lead
Exposure Yes Yes Yes Yes Yes
Effect Yes No Indicative, not deﬁnitive Yes Not known
Susceptibility Indicates speciﬁc  No No No No
response to compound K
Evaluation characteristics
Persistence Yes No No No Yes
Ease of collection Readily collected Readily collected Readily collected Somewhat difﬁcult Difﬁcult
Link to disease Direct between exposure,  Unclear. Cotinine is a marker  Established link between Established link between No direct link. Endogenous
source, and disease for smoking, but has not been  exposure to lead and  exposure to lead and  source of lead from bone
implicated as a causative agent neurologic disease neurologic disease may be important
Large sample  Large percentage of Those who smoke or are  Yes Yes Yes
population carries  exposed to ETS
biomarker
Broad spatial  Occurs across racial and  Those who smoke or are  Yes Yes Yes
distribution geographic boundaries exposed to ETS
Appropriate  Occurs over time scales  No, short half-life for  No, recent past exposure No, recent past exposure Yes
temporal associated  with  carcinogenesis end point
progression of disease
Sensitivity Displays dose response Unclear  Some indications Some indications Not known, few studies
Parent compound Directly measures K Closely associates with nicotine Direct measure of lead Direct measure of lead Direct measure of lead
Abbreviations: ETS, environmental tobacco smoke; K, hypothetical compound for which an ideal biomarker is available.then one must be concerned about differential
susceptibility in the population; a biomarker of
susceptibility is needed. Thus the “ideal” bio-
marker may not exist. 
Application of array concept—
organophosphate pesticides. It may be possible
to approach the ideal biomarker functionally
by applying an array of biomarkers, each of
which provides some of the ideal characteris-
tics. For example, organophosphate pesticides
(OPs) have widely varying chemical structures
but share a common toxic mechanism of
action: acetylcholinesterase inhibition.
Although exposure to OPs has been linked to
neurologic effects, this primary mechanism of
action is actually a short-term, or early, effect
(Figure 1). 
Biomarkers of exposure to these com-
pounds exist. Dialkyl phosphates (DAPs) (Barr
et al. 2004) and OP-speciﬁc (or near-speciﬁc)
biomarkers such as 3,5,6-trichloro-2-pyridinol
(TCPy) (Barr et al. 2005b; MacIntosh et al.
1999) offer two approaches to assessing OP
pesticide exposure. The nonspeciﬁc biomarker
for OPs, DAPs, may offer insight into the gen-
eral exposure to these pesticides and a pathway
to cumulative risk assessment, whereas the OP-
speciﬁc biomarker gives insight into exposure
to speciﬁc members of this class, for example,
chlorpyrifos (and chlorpyrifos-methyl) and
some insight into metabolic processes.
Measurement of the compound-specific bio-
marker, for example, TCPy, can give informa-
tion only on exposure to the compounds from
which it is derived. Further, interpretation is
complicated because of levels of TCPy in expo-
sure media (Lu et al. 2006; Morgan et al.
2005; Wilson et al. 2004). Degradation of the
parent compound in environmental media,
including food, and subsequent intake of the
degradation product may lead to overestima-
tion of the intake of the parent compound,
reducing the effectiveness of such a biomarker
in inferring exposure. Although the DAPs
measure gives information on all compounds
of this general class, each member of the OP
class has different inhibition characteristics.
The measure of the nonspecific metabolites
does not give information on the speciﬁc com-
pound from which they came, reducing,
although not eliminating their use. 
Directly measuring acetylcholinesterase
inhibition, a biomarker of effect, may add some
insight into susceptibility, but it provides no
information on the cause of inhibition. Recent
work (Costa 2006; Costa et al. 2005) suggests
that polymorphisms in paraoxonase may offer a
direct biomarker of susceptibility with regard to
OPs, but more research is needed to establish
relationship norms for this marker. The discus-
sion above suggests that the simultaneous col-
lection of all three biomarkers is likely to lead to
substantially more information than collection
of the individual markers alone.
A Framework for Applying an
Array of Biomarkers and Other
Metrics
The framework presented in Figure 1 provides
the conceptual basis for considering an array of
biomonitoring data and other health metrics in
assessment of cumulative exposure and risk.
The receptor may be a human being, an indi-
vidual organism, a population, a community,
or an ecosystem. Multiple sources result in
environmental conditions ranging from tem-
poral and spatial exposures to multiple stressors
(Sexton and Hattis 2007). These multiple
exposures at varying times may be required to
induce any one outcome. 
The framework uses the following bio-
markers: 
• biomarkers of susceptibility to characterize
the receptor (e.g., information on genetics,
developmental or life stage, health status,
age, preexisting disease, nutritional status)
(deFur et al. 2007); 
• biomarkers of effect to characterize the
potential for or existence or prevalence of
adverse outcomes (e.g., may range in scale
from early effects detectable at a molecular
level to manifestations of the full disease
state); and 
•biomarkers of exposure to characterize
direct impact of stressors on the receptor
(Menzie et al. 2007). 
Linking these internal markers of expo-
sure to associated chemical, biological, physi-
cal, or psychosocial stressors often will require
consideration of additional information on
conditions of the environment and inter-
action of the receptor with the environment.
In addition, it is important to link the timing,
duration, and route of exposure as well as the
kinetics of uptake and elimination for a given
set of chemicals to the biomarker of exposure.
Applying the framework. Multiple
sources. Even for a specific contaminant,
there is the potential for multiple sources and
pathways of exposure. For example, in the
case of OPs, a receptor can be exposed
through various sources including ingestion
of agricultural crops or direct contact from
local application for pest control. Each of
these sources results in environmental conta-
mination, but the movement through the
environment that produces the resulting
exposure is substantially different. One may
attempt to monitor the food supply, house
dust, soil, and air concentrations (the expo-
sure) and infer dose to the receptor through a
modeling process that estimates intake to the
body based on the amount of specific com-
pound found in each of the media. However,
such calculations are difﬁcult and results may
depend upon the model selected. 
Factors inﬂuencing effects. Three factors of
interest inﬂuence the effects observed on the
receptor: genetic susceptibility, developmental
stage, and health status (Figure 1). Genetic
susceptibility—for example, through differen-
tial metabolism of OPs among various indi-
viduals, communities, or populations—may
result in different effects for a given exposure.
Developmental stage is an important determi-
nant of the effects of exposure. Perhaps the
most visible case of such effects occurred in
the so-called thalidomide babies born to
mothers who took this drug in the early
1960s. Developmental stage was critical; those
Biomarkers in cumulative risk assessment
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Figure 1. Framework for biomonitoring.
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Markers of effect Markers of exposurewho were exposed to thalidomide at a particu-
lar stage of gestation suffered from the expo-
sures, whereas others exposed later in
gestation, or not at all, did not experience any
such effects. For effects (Figure 1, right side),
various levels of outcomes range from often
subclinical “early effects” through altered
structure and function, leading to a measured
adverse outcome. It is important to note that a
dose from a single chemical may lead to multi-
ple early effects, altered structure and func-
tions, and outcomes. For example, exposure to
lead may lead to cognitive and neurologic
effects (Stewart et al. 2006) and altered blood
pressure status (Glenn et al. 2003). Thus, one
progresses from a multifactorial source–expo-
sure–dose relationship, modified by receptor
status with respect to development, suscepti-
bility, and health, to multifactorial outcomes.
Health status of the receptor. Health status
of the receptor can also affect the outcome of a
given exposure. Those with compromised
immune systems due to disease status, or those
with, for example, little excess pulmonary
capacity, may be more adversely affected to a
given exposure than those not suffering from
these conditions. Similarly, an ecosystem under
stress from, for example, ozone exposure, may
respond differently to herbicides than a health-
ier ecosystem (Menzie et al. 2007; Sexton and
Hattis 2007). The key question becomes “How
do we think about the appropriate array of bio-
markers needed to assess fully the outcomes of
interest for the speciﬁc receptor?”
Setting a Research Agenda 
The review of biomarker data indicates that
there probably is no single, ideal biomarker
(e.g., Table 1), and the discussion of using an
array of biomarkers to assess the cumulative
effects of various contaminants, poses various
established uncertainties (e.g., a full suite of
biomarkers—exposure, susceptibility, and
effect) may not exist for a speciﬁc compound.
However, we believe that an integration of the
characteristics of an ideal biomarker with
existing knowledge of the speciﬁc difﬁculties
surrounding a speciﬁc outcome of concern can
offer research recommendations. This is a sim-
ple matrix that matches a set of evaluation cri-
teria (the criteria that define an ideal
biomarker) to the current state of knowledge
(an array of existing biomarkers and other
health criteria). One can use that knowledge
to ﬁll the matrix and specify the uncertainties
associated within each match-up. Figure 1
presents the essentials of the matrix. At a mini-
mum, the questions addressed in each element
should include the following: 
• Does the biomarker have the desired criteria?
• Are there multiple sources that affect the
biomarker?
• Is the biomarker indicative of genetic status?
• Is the biomarker indicative of developmental
stage?
• Is the biomarker indicative of health status?
• Are there many potential outcomes (e.g.,
multiple early effects, altered structure and
functions, and changed health status)?
The answers to these questions, informed by
the ideal criteria, will produce a coherent
research agenda suitable to prioritization. 
Biomarkers and Disease
Outcomes—Illustrative Case
Studies
Until now the focus has been on the exposure
side, approaching biomarkers as a method of
assessing exposure experienced by a receptor
to some environmental contaminant. We
now change the focus to outcome. We pose
the question “Can the presence of certain bio-
markers in the receptor aid in evaluating the
source of a particular health outcome?” Two
cases studies are presented on disease out-
comes of concern: asthma and neurobehav-
ioral effects. Both are complex diseases with
many different causes and manifestations.
Both have multiple biomarkers, including
those of exposure, effect, and susceptibility,
that can be used singularly or in combination
to assess the contaminant sources affecting the
disease and the disease outcome. We propose
to evaluate multiple biomarkers simultane-
ously, the main proposal advocated in this
work. For one of these cases, asthma, the
matrix in Table 2 is applied to assess the sta-
tus of each associated biomarker relative to
the ideal. Also for this case, we present the
graphical framework (Figure 2).
Asthma and asthma etiology markers and
effects. Background. Asthma and related aller-
gic diseases (ADs) are manifested by numer-
ous environmentally related sources, and
numerous potential outcomes. In the United
States, recent surveys find a 16% prevalence
Ryan et al.
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Table 2. Asthma: example evaluation for the outcome.
Biomarkers and health metrics associated with asthma
Characteristics of an  IgE  Th2 cytokine pattern 
ideal biomarker RAST-positivity predominance Skin rashes Food allergies
Persistence Good Good Irregular Good
Ease of collection Difﬁcult Difﬁcult Clinical evaluation Clinical evaluation
Link to disease Possibly Possibly Possibly Possibly
Large sample  Yes Yes Unknown Unknown
Broad spatial  Yes Yes Unknown Unknown
distribution
Appropriate temporal  Yes Yes Possibly Possibly
occurrence
Sensitivity No No Possibly Possibly
Parent compound NA NA NA NA
Abbreviations: NA, not applicable; RAST, radioallergoabsorbent test; Th2, T-helper 2.
Figure 2. Framework applied to asthma case study. Abbreviations: ETS, environmental tobacco smoke; PM,
particulate matter; NO2, nitrogen dioxide; RAST, radioallergoabsorbent test; Th2, T-helper 2; VOCs, volatile
organic compounds.
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IgE-RASTof asthma among children 14 years of age,
with a 200% increase in the rate of asthma
hospitalizations and a 100% increase in the
rate of asthma mortality since the 1970s. The
“atopic march” is the accepted natural history
of ADs and refers to a sequence of early
immunologic and later clinical responses that
may appear in young children, persist over
years, and may continue throughout one’s
lifetime (Kulig et al. 1999). A series of bio-
markers may afford an improved understand-
ing of the effects of various sources on the
etiology of these related diseases. Examination
of the contaminant sources thought to inﬂu-
ence the course of the atopic march and the
biological markers associated with this process
is instructive in light of the concepts pre-
sented in this article.
Sources and exposures. There is much
evidence to suggest that components of the
early childhood indoor and outdoor environ-
ments are contributing to the increasing
prevalence of ADs (Figure 2). Various air-
borne sources are associated with the etiology
of ADs and the specific development of
asthma. These include: photochemical and
particulate air pollution (Andrae et al. 1988;
Diaz-Sanchez et al. 1997; Lunn et al. 1970;
Peterson and Saxon 1996; Ussetti et al. 1984;
Ware et al. 1986); criteria air pollutants,
diesel exhaust carbon particles, and pesticides
that increase allergic sensitization (Behrendt
et al. 1997; Emberlin 1995; Knox et al. 1997;
MacIntosh et al. 1999; Rubbin et al. 1986;
Rufﬁn et al. 1986); and, elevated airborne lev-
els of particulate matter (PM), particularly
ﬁne aerosol (particulate matter with an aero-
dynamic diameter ≤ 2.5 µm) (Dejmek et al.
1999; Neas et al. 1994; Norris et al. 1999;
Romieu et al. 1996). Speciﬁc biomarkers for
many of these pollutants are not yet available.
Individuals living in industrialized societies
also tend to spend a larger fraction of time in
indoor environments that have higher allergen
and chemical burdens (Platts-Mills et al.
1996). There is some evidence that indoor
exposure to volatile organic compounds can
be related to asthmatic symptoms (Harving
et al. 1991). Among infants exposed to envi-
ronmental tobacco smoke, studies demon-
strate that the risks of lower airway disease and
recurrent wheezing are increased (Arshad and
Hide 1992; Murray and Morrison 1990;
Wahn and von Mutius 2001). Exposure to
household endotoxin may also be important
in the development of ADs. There is evidence
that high levels of household endotoxin may
mitigate the development of ADs before dis-
ease onset but may exacerbate the symptoms
of ADs once developed (Gereda et al. 2000,
2001; Park et al. 2001). 
Biomarkers of susceptibility, exposure,
and effect. Several biological markers of
nascent hypersensitivity exist (Figure 2). These
include IgE, Radioallergoabsorbent test
(RAST)-positivity, T-helper type-2 (Th2)
cytokine pattern predominance. These mark-
ers indicate imbalance in the development of
the immune system in newborns and young
children and early clinical manifestations of
ADs including early development of food
allergies and atopic dermatitis manifested as
skin rashes. Both genetic and environmental
factors have been implicated (Miller 2001).
One early marker for atopic immunoreactivity
in infancy is the presence of IgE antibody to
egg or cow’s milk in serum. The ﬁrst clinical
manifestation of atopic immunoreactivity is,
typically, atopic dermatitis, with the highest
incidence during the ﬁrst 3 months of life, fol-
lowed by food allergy (Wahn and von Mutius
2001). Those individuals who develop the
early clinical manifestations, including food
allergies and atopic dermatitis, are at higher
risk for persistent asthma (Martinez et al.
1995). Thus, measure of these markers may be
viewed as early indicators of altered structure
or function (Figure 2).
The combination of the measurement of
multiple biomarkers of susceptibility and
effect coupled with better measures of expo-
sure to multiple pollutants is likely to lead to
a more complete understanding of the pro-
gression of ADs and the increased incidence
and prevalence of asthma in modern, indus-
trialized societies. Disaggregation of the
effects is still problematic. Despite the pres-
ence of measures of early effect, few data have
been collected that show the path of causality
from source, (e.g., criteria pollutants),
through biomarker (e.g., Th2 cytokine path
dominance), to the onset of asthma. 
Neurobehavioral end points. Background.
Several neurobehavioral end points have been
linked to environmental exposures (see
Supplemental Material, Figure 1, for a graphi-
cal depiction of this link; http://www.
ehponline.org/docs/2007/9334/suppl.pdf).
Some important known behavioral neurotox-
ins include mercury and lead. However, mak-
ing speciﬁc chemical/exposure links is difﬁcult
because the causes of human disease are var-
ied—resulting from a mixture of environmen-
tal, lifestyle, socioeconomic, and genetic factors
acting over the life time of the individual. 
Examples of neurobehaviorally active sub-
stances with multiple exposure pathways.
Mercury. Mercury is a neurotoxic substance
that can produce a wide range of health effects
depending on the amount and timing of expo-
sure (Clarkson 1997; Ratcliffe et al. 1996; U.S.
EPA 1997). Mercury is a naturally occurring
element found in the earth’s crust, but human
activities contribute signiﬁcantly (an estimated
70%) to the amount of mercury circulating in
the environment (Kyerematen and Vesell
1991). Because of its persistence and the large
and distributed number of sources, almost
everyone will be exposed to low levels of mer-
cury in air, water, or food (U.S. EPA 1997). 
Mercury is somewhat persistent in human
tissues (U.S. EPA 1997). This makes it feasi-
ble to assess human exposure using blood,
hair, and urine. Concentrations of mercury in
maternal blood, cord blood, and maternal
hair have been used to asses the potential for
developmental neurobehavioral end points,
but there are signiﬁcant interindividual vari-
abilities in the relationship among blood-to-
hair, blood-to-intake, or hair-to-intake ratios
(Bartell et al. 2000). In addition to hair and
cord blood, other biomarkers are emerging.
For example, mercury selectively alters por-
phyrin metabolism in kidney proximal tubule
cells, leading to an altered urinary porphyrin
excretion pattern (Woods 1996), thereby
offering a biomarker of effect. 
Lead. Lead is a naturally occurring heavy
metal widely distributed in the Earth’s crust
and found in soil, surface water, groundwater,
and vegetation and animal tissues. The human
body has no known biological need for lead,
but once taken in by ingestion, inhalation, or
dermal contact, lead behaves like calcium in
the body and is stored mostly in the bones,
with a small fraction in the blood. The levels of
lead in the blood reach equilibrium with bone
levels, but this often takes months, even years.
Short-term high or low rates of intake can dis-
rupt this equilibrium (Chuang et al. 2001). 
Exposures to lead occur in occupational
and residential settings. Children and most
adults in the United States are more likely to
experience chronic low-to-moderate-level lead
exposure than acute, high-level exposure.
Among the most signiﬁcant health prob-
lems associated with these levels of lead are
neurologic development problems. In adults
and children, chronic lower/moderate-level
lead exposure has been associated with learn-
ing deﬁciencies, memory problems, behavior
problems, attention deficit, problems with
coordination, anemia, digestive disorders,
renal dysfunction, abnormal reproductive
function, and possible infertility (Needleman
and Bellinger 1991). 
The level of lead in the blood is most often
used as the measure of the amount of lead in
the body. However, blood lead only relates to
the lead exposure within the past few months
Currently available tests are subject to numer-
ous limitations such as unreliability and lack of
sensitivity for values below a few micrograms
per deciliter in blood (Table 1.) This limitation
is signiﬁcant because similar blood lead con-
centrations have recently been shown to induce
irreversible neuropsychologic damage in chil-
dren (Tong et al. 1998). Like mercury, lead
persists in the body so that levels in blood, hair,
and bone have served as biomarkers of lead
exposure. Lead in teeth and bones can be meas-
ured with X rays, but this test is not readily
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available (Table 1.) One factor limiting the
progress of lead epidemiology has been the
absence of a biomarker of long-term exposure.
Therefore, considerable effort has been devoted
to developing methods for the in vivo measure-
ment of lead deposited in bone. 
Effects in children. Human diseases have
numerous causative factors that result from a
mixture of environmental, lifestyle, socio-
economic, and genetic factors acting over the
lifetime of the individual. However, in most
cases the environment influences, in varying
degrees, the initiation, severity, and/or progres-
sion of disease (SB 702 Working Group
2004). Children are particularly vulnerable to
environmental disease because their bodies are
still developing; they are exposed to more cont-
aminants on a body-weight–adjusted basis; and
behaviors such as crawling, putting objects in
their mouths, and running that can increase
their environmental exposures. Among the
most serious diseases confronting children in
the United States are neurodevelopmental and
behavioral disorders. The manifestation of
these diverse effects may arise through expo-
sures to compounds such as mercury and lead
in that similar (and multiple) effects may be
noted for more general exposure to diverse
compounds in the environment. 
We consider three effects seen in children
that may have etiology rooted, at least in part,
in environmental exposure: developmental
disorders, attention deﬁcit hyperactivity disor-
der (ADHD), and delinquency. Examination
of these effects in conjunction with multiple
sources may offer a fruitful pathway for fur-
ther understanding.
Developmental disorders. Although chemical
exposure may be one of the most preventable
causes of developmental disorders, the scope of
this problem has not been well defined, and
there have been only limited attempts at con-
certed research efforts to use biomarkers to
assess cumulative exposures for all substances
linked to developmental disorders. So the ques-
tion to consider is “Are the substances cur-
rently known to have effective biomarkers
likely to be the ones that will be the dominant
contributors to developmental end points?”
There has been recent concern that a sig-
nature metabolic impairment or “biomarker”
in autistic children strongly suggests that
these children would be susceptible to the
harmful effects of mercury and other toxic
chemical exposures (Parker et al. 2004). To
address this issue, the Centers for Disease
Control and Prevention conducted its own
epidemiologic study and then convened a
panel of the Institute of Medicine (IOM) of
the National Academy of Sciences to review
the issue independently. On 17 May 2004,
the IOM published its ﬁnal report on the pos-
sible link between thimerosal and autism and
concluded that neither the mercury-based
vaccine preservative thimerosal nor the
measles–mumps–rubella (MMR) vaccine are
associated with autism (IOM 2004). These
ﬁndings remain controversial, and biomarkers
could play a role in further confirming or
challenging this ﬁnding. 
Attention deﬁcit hyperactivity disorder. The
causes of ADHD are currently not known,
but the disorder appears to involve both
genetic and environmental components.
Possible causes of ADHD include physical
trauma to the brain, problems during preg-
nancy or delivery, genetic abnormalities, and
differences in brain structure (National
Institute of Mental Health 2005) in addition
to or in concert with environmental exposures.
There is evidence that environmental expo-
sures can cause problems with behavior and
attention similar to those seen in children with
ADHD. However, there is little evidence that
environmental exposures clearly cause
ADHD. For example, many human studies
demonstrate that children with elevated lead
levels have problems with behavior, impulsiv-
ity, and concentration. Several individual case
studies suggest that lead exposure may be
linked with ADHD. But these studies do not
clearly show that lead exposure causes ADHD.
Similarly, several human studies suggest that
children exposed to methylmercury have an
increased risk of behavioral problems.
However, this ﬁnding is controversial. Not all
studies support this association (NRC 2000). 
Delinquency. Lead exposure has been asso-
ciated with increased risk for antisocial and
delinquent behavior, and the effect follows a
developmental course (Needleman et al. 1996).
This association links elevated bone lead con-
centrations and the risk of being arrested for
criminal behavior. The underlying causes for
this association are not certain. One possibility
is that lead interferes with impulse control and
that people who have difficulty controlling
impulses are more likely to engage in criminal
behavior. Another possibility arises from lead’s
well-established impact on cognitive function
and classroom performance. 
In Supplemental Material (http://www.
ehponline.org/docs/2007/9334/suppl.pdf), we
present an additional case study (“Endocrine
Disruptors—An Ecological Point of View”)
that uses an ecosystem as a potential sentinel
biomarker.
Summary and 
Recommendations 
In this article, we have identified two focus
points for evaluating the capabilities of bio-
monitoring data: a) Under what circum-
stances can biomarkers be used to disaggregate
disease burden into specific risk factors? and
b) When and how can biomarkers be used to
infer the source and magnitude of exposure
among a set of competing sources and
pathways? In the following section, we use the
case studies above as well as information in
the literature on the availability and use of
biomarkers to evaluate the capabilities of bio-
markers to address these two focus points for
cumulative risk assessments. 
Use of biomarkers to disaggregate disease
burden into specific risk factors. The use of
biomarkers to disaggregate disease burden into
specific risk factors is an extension of classic
epidemiologic methods, with biomarkers used
in place of, or together with, other classiﬁca-
tion factors. Here, the role of biomarkers is to
improve resolution in classifying observed dis-
ease occurrence by providing factors that are
more explicitly causative or explanatory. This
allows for the greatest opportunity of learning
to integrate markers of exposure with markers
of effect and markers of susceptibility.
Some existing studies have demonstrated
the clear advantage of biomarkers for sorting
out important risk factors, but much remains
to be done. For example, with lead and mer-
cury, the blood levels serve as biomarkers of
exposure that have been important as risk fac-
tors for disease. These risk factors are suffi-
ciently reliable that biomonitoring for lead and
mercury have shaped prevention strategies,
helped susceptible subpopulations, and
improved the scientific basis for health risk
estimates. For neurologic effects, blood lead
measurements have been used both as markers
of exposure and markers of effect because the
harm to the neurologic system depends on the
amount of circulating lead in the body.
Cotinine has proved useful as a biomarker of
exposure to environmental tobacco smoke but
is not optimum as a biomarker of effect
because cotinine is a metabolite of nicotine
that is subject to interindividual variability in
measured concentration. To date most efforts
to use biomarkers to improve the links among
disease patterns and risk factors have been hap-
hazard and opportunistic. In the example of
substances as well as the broader range of sub-
stances having available biomarkers, there is
need for a systematic effort to evaluate whether
and how links among exposure and other risk
factors can be better tracked to disease burden.
Use of biomarkers to infer contributions
from different sources and pathways. Most
environmental pollutants enter human and
ecologic receptors from multiple sources and
through competing pathways. Effective policies
require cumulative risk assessments that not
only provide reliable estimates of cumulative
intake but also identify the important sources
and exposure pathways contributing to this
intake. It is common in most risk assessments
that this calculation is made in the forward
direction—from source to dose. But the
increasing availability of population-scale bio-
monitoring data makes in possible to work in
the opposite direction from dose to source.There have been some preliminary efforts to
use biomarkers to infer sources and pathways,
but such efforts have been limited. There
remains the need for efforts to articulate
and evaluate strategies for systematically using
biomarkers to infer source and pathway. 
The case studies above provide prelimi-
nary examples of when and how biomarkers
can be used to infer the source and magnitude
of exposure among a set of competing sources
and pathways. The answer to this question is
chemical speciﬁc and relates to how well the
biomarker matches the characteristics of an
“ideal” biomarker, in particular, ease of collec-
tion and persistence. For example, the dioxins
and polychlorinated biphenyls, which are per-
sistent in biological organisms, facilitate bio-
monitoring that has enabled scientists and
public health professionals to track population
trends and to evaluate progress in reducing
exposures. To some extent, biomarkers of
dioxin-like substances have also been useful in
demonstrating for these compounds the rela-
tive importance of global versus regional and
local source as well as important contributions
through food rather than inhalation pathways.
In contrast, biomarkers of a compound that is
metabolized relatively quickly provide only
limited opportunity for inferring sources or
exposure pathways. Biomarkers for OPs are
somewhere between the extremes of dioxin-
like compounds and rapidly metabolized com-
pounds in providing an opportunity to
explore source and pathway contributions.
OPs can be measured directly in blood (and
possibly in urine) and produce both generic
metabolites—DAPs—and OP-specific (or
near-speciﬁc) biomarkers such as TCPy. The
use of these biomarkers in combination pro-
vides a better opportunity to disaggregate both
source and pathway contributions than is pos-
sible for a rapidly metabolized compound.
However, little has been done to explore the
capabilities and limitations of using multiple
biomarkers in combination to infer exposure
attributes. One example discussed is the direct
intake of the biomarker itself giving rise to an
over-estimate of exposure; there are likely oth-
ers. Important goals for near-term biomarker
research must include systematic efforts across
a broad range of chemical substances to deter-
mine the reliability of biomarkers to infer the
source and exposure pathway in cumulative
risk assessments. This may be done most effec-
tively through the simultaneous collection of
biomarker data of various types on the same
individuals, populations, or ecosystems.
In conclusion, the public health goal of
quantifying the burden of disease that is
attributable to the cumulative impacts of envi-
ronmental exposure remains elusive. However,
the steady progress in development of bio-
markers of exposure, susceptibility, and effect,
coupled with emerging technologies for
environmental monitoring, offers unprece-
dented opportunities to examine and prevent
cumulative health risks and to redefine
approaches to environmental protection. 
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